Profil
Lynn Gallant worked as Vice President-Clinical Operations at BlueRock Therapeutics Canada ULC and Enveric Biosciences, Inc. Ms. Gallant obtained an undergraduate degree from the University of New England.
Anciens postes connus de Lynn Gallant
| Sociétés | Poste | Fin |
|---|---|---|
| ENVERIC BIOSCIENCES, INC. | Directeur Technique/Scientifique/R&D | 01/05/2023 |
BlueRock Therapeutics Canada ULC
 BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada. | Directeur Technique/Scientifique/R&D | - |
Formation de Lynn Gallant
| University of New England | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ENVERIC BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
BlueRock Therapeutics Canada ULC
BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada. | Health Technology |
